Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes

National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study

(2016) Carlos A. Puig et al.   ANNALS OF SURGICAL ONCOLOGY

Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study

(2016) Akiko Chiba et al.   ANNALS OF SURGICAL ONCOLOGY

A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

(2016) SATORU TANAKA et al.   ANTICANCER RESEARCH

The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy

(2016) Elizabeth A. Mittendorf et al.   JAMA Oncology

Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors

(2015) Zahraa Al-Hilli et al.   ANNALS OF SURGICAL ONCOLOGY

Landscape of Neoadjuvant Therapy for Breast Cancer

(2015) Tufia C. Haddad et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant treatment of breast cancer – Clinical and research perspective

(2015) Sibylle Loibl et al.   BREAST

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

(2015) Sarah S. Mougalian et al.   CANCER

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer

(2014) Judy C. Boughey et al.   ANNALS OF SURGERY

Current and future role of neoadjuvant therapy for breast cancer

(2014) Michael Untch et al.   BREAST

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

(2014) Kunpeng Wu et al.   World Journal of Surgical Oncology

Individualizing breast cancer treatment—The dawn of personalized medicine

(2013) Argha Nandy et al.   EXPERIMENTAL CELL RESEARCH

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

(2011) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Using the NCDB for cancer care improvement: An introduction to available quality assessment tools

(2009) Mehul V. Raval et al.   JOURNAL OF SURGICAL ONCOLOGY